MOTS-C (5 mg Vial)

MOTS-C Research Reference

MOTS-C is referenced at 500 mcg–2 mg daily in educational research settings. A 5 mg vial prepared with bacteriostatic water provides approximately 1.67 mg/mL. Research references commonly discuss gradual adjustments over roughly 10 weeks. This information is provided for research and educational use only.

MOTS-C is a 16-amino-acid mitochondrial-derived peptide encoded in the mtDNA 12S rRNA region. Discovered in 2015, it has been studied for its role in metabolic homeostasis through AMPK activation, exercise-related responses, and age-related changes. This educational reference presents general scientific information aligned with preclinical findings and emerging research.

Research context: For evidence on mechanisms, human and preclinical research, limitations, and safety information, read MOTS-C Peptide: Benefits, Uses, Research Background.

Educational guide for preparation and daily reference information

Standard / Gradual Approach (3 mL = ~1.67 mg/mL)

Week	Daily Research (mcg)	Units (mL)
Weeks 1–2	500 mcg (0.5 mg)	30 units (0.30 mL)
Weeks 3–4	1000 mcg (1.0 mg)	60 units (0.60 mL)
Weeks 5–6	1500 mcg (1.5 mg)	90 units (0.90 mL)
Weeks 7–8	2000 mcg (2.0 mg)	120 units (two 60‑unit)*

Frequency: Apply once daily subcutaneously (morning application preferred). For 2.0 mg reference amounts (120 units total), divide into two separate 60-unit applications at different areas, or use a more concentrated 2.0 mL preparation (2.5 mg/mL → 80 units for 2 mg).

<b>Alternative Approach:</b> Some research references discuss different weekly application patterns at higher individual amounts; consult available literature for additional information.

Preparation Steps

Important: This guide is for educational purposes only and is not medical advice. For research reference only. Not for human consumption.

Plan based on an 8–16 week daily research schedule with gradual adjustment.

Concise summary of the once-daily research approach based on preclinical evidence.

Goal: Support metabolic homeostasis, enhance insulin sensitivity, and promote healthy aging through AMPK activation.
Schedule: Daily subcutaneous application reference for 4–8 weeks, followed by an equal-length break (cycling approach).
Reference Range: 500–2000 mcg daily with gradual adjustment over weeks.
Preparation: 3.0 mL per 5 mg vial (~1.67 mg/mL) for accurate unit measurements.
Storage: Lyophilized material frozen at −20 °C (−4 °F); prepared solution refrigerated at 2–8 °C (35.6–46.4 °F); use within 2–4 weeks.

Suggested daily adjustment approach aligned with preclinical models.

Start: 500 mcg (0.5 mg) daily for weeks 1–2; conservative baseline amount.
Adjustment: Increase to 1000 mcg (1.0 mg) daily for weeks 3–4, then 1500 mcg (1.5 mg) for weeks 5–6.
Target: 1500–2000 mcg (1.5–2.0 mg) daily by weeks 7–8 if well-tolerated.
Frequency: Once per day (subcutaneous); morning application preferred to mimic exercise-induced release patterns.
Cycle Length: 4–8 weeks on, followed by 4–8 weeks off; avoid continuous long-term use without breaks.
Timing: Consistent daily timing; rotate application areas (abdomen, thighs, upper arms).

Proper storage preserves peptide quality and stability.

Lyophilized: Store at −20 °C (−4 °F) in dry, dark conditions with desiccant; stable for months to years when frozen.
Prepared: Refrigerate at 2–8 °C (35.6–46.4 °F); use within 2–4 weeks for optimal stability.
Handling: Allow materials to reach room temperature before opening to reduce condensation; avoid repeated freeze–thaw cycles.
Protection: Protect from light and moisture; use clean handling practices when withdrawing material.

Practical considerations for consistency and safety.

Material Handling: Use new sterile measurement devices for each application; dispose of used materials in a proper sharps container.
Area Rotation: Rotate application areas systematically (abdomen, thighs, upper arms) to reduce local irritation and lipohypertrophy risk.
Application Method: Apply slowly; wait a few seconds before removing the device to ensure complete delivery.
Documentation: Record daily amount, time, and area rotation to maintain consistency and monitor response.
Measurement Reference: If amounts fall below 30 units (0.30 mL), consider using suitable measurement devices for improved readability.
Higher Amount Reference: For 2.0 mg amounts exceeding single-device capacity (>100 units), divide into separate applications or use a 2.0 mL preparation.

MOTS-C is a mitochondrial-derived peptide that activates AMPK-driven metabolic pathways to enhance glucose uptake, increase fat oxidation, and reduce lipid accumulation in muscle and adipose tissue. Preclinical studies demonstrate that daily MOTS-C administration in animal models supports metabolic responses related to diet-induced obesity and insulin resistance, while shorter-term research has explored changes in insulin sensitivity. Unlike metformin (which acts primarily in the liver), MOTS-C directly targets skeletal muscle and fat tissues. The peptide may also influence nuclear signaling under metabolic stress to regulate gene expression. Endogenous MOTS-C levels rise with exercise and may change with age, suggesting potential research interest in age-related metabolic pathways. Current human research remains limited, and available information is based primarily on preclinical findings.

Observations from preclinical models and emerging research information.

Metabolic Support: Enhanced insulin sensitivity and glucose metabolism in muscle and fat tissue.
Fat Metabolism: Increased fat oxidation and reduced diet-induced obesity responses in animal models.
Exercise Response: Improved exercise capacity and muscle homeostasis during aging research.
Lifespan Research: Modest lifespan extension observed in rodents with intermittent administration patterns (15 mg/kg 3×/week).
Growth Pathway Research: No stimulation of IGF-1 or adverse effects on glucose tolerance (contrast with growth hormone).
Tolerance Observations: Well-tolerated in animal studies with no severe adverse responses at typical amounts.

Local Responses: Mild area-related responses (temporary redness, inflammation, or bruising) have been reported anecdotally.
Safety Observations: No severe adverse effects or organ toxicity observed in preclinical studies at standard amounts.
Long-Term Information: Long-term human safety data are not yet available; continuous use beyond 8 weeks remains uncharacterized.
Extended Use Consideration: Theoretical risk of downregulation with prolonged daily use; cycling approach (4–8 weeks on, equal time off) is commonly discussed.

Complementary strategies for optimal metabolic outcomes.

Nutrition: Pair with a balanced, protein-forward diet tailored to energy needs; MOTS-C research explores nutrient partitioning and fat utilization.
Exercise: Combine resistance training and aerobic activity to support AMPK activation and metabolic adaptations.
Sleep: Prioritize 7–9 hours of quality sleep; MOTS-C research explores mitochondrial function, while recovery remains essential.
Stress Management: Manage stress through mindfulness or relaxation practices; chronic stress can influence metabolic pathways.
Hydration: Maintain hydration and consider timing around fasting periods (e.g., morning before breakfast) to align with metabolic patterns.

General subcutaneous application guidance from available best-practice resources.

Clean the vial stopper and application area with alcohol swab; allow to air-dry.
Pinch a skinfold (1–2 inches) at the chosen area; place the device at 45–90° into subcutaneous tissue.
Avoid aspiration for subcutaneous application; apply slowly and steadily over 2–5 seconds.
Remove the device at the same angle; apply gentle pressure with a clean cotton ball or alcohol pad (do not rub).
Rotate application areas systematically (abdomen at least 2 inches from navel, outer thighs, upper arms) to avoid lipohypertrophy or scar tissue.
Allow refrigerated solution to reach room temperature for 5–10 minutes before application to reduce discomfort.
Dispose of used materials immediately into a puncture-proof sharps container; do not recap the device.

This content is intended for educational purposes only and does not constitute medical advice, diagnosis, or treatment. MOTS-C is an experimental research peptide intended for laboratory research purposes only. Information provided here is for educational reference and should not be considered a recommendation for personal use. Any discussion of amounts or application methods is presented for informational purposes only. Individual responses may vary. Consult a qualified healthcare professional regarding any health-related decisions.

Journal of Translational Medicine (2023)

— Wan W, et al. Mitochondria-derived peptide MOTS-C: effects and mechanisms related to stress, metabolism and aging

Cell Metabolism (2015)

— Lee C, et al. The mitochondrial-derived peptide MOTS-C promotes metabolic homeostasis and reduces obesity and insulin resistance

Nature Communications (2021)

— Reynolds JC, et al. MOTS-C is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis

Alzheimer’s Drug Discovery Foundation (2021)

— Cognitive Vitality Profile: MOTS-C evidence review detailing preclinical findings and safety

CDC

— Vaccine Administration: subcutaneous route guidance; angle, site selection, and related considerations

CDC

— Subcutaneous application technique: PDF guidance and site information

NCBI Bookshelf

— Best practices for subcutaneous application: aseptic preparation, administration, and site rotation

Bachem

— Peptide storage and handling information for lyophilized and prepared materials

Peptide Crafter (2025)

— Stability study of MOTS-C peptide following preparation and refrigerated storage (lab report with purity data over 30 days)

GenScript

— Peptide storage and handling information: freeze–thaw considerations and best practices